|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PDZK1IP1 |
Gene summary for PDZK1IP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PDZK1IP1 | Gene ID | 10158 |
| Gene name | PDZK1 interacting protein 1 | |
| Gene Alias | DD96 | |
| Cytomap | 1p33 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q13113 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10158 | PDZK1IP1 | GSM4909281 | Human | Breast | IDC | 5.80e-05 | -3.55e-01 | 0.21 |
| 10158 | PDZK1IP1 | GSM4909282 | Human | Breast | IDC | 9.21e-16 | 5.44e-01 | -0.0288 |
| 10158 | PDZK1IP1 | GSM4909286 | Human | Breast | IDC | 1.03e-24 | -6.23e-01 | 0.1081 |
| 10158 | PDZK1IP1 | GSM4909287 | Human | Breast | IDC | 1.58e-09 | -4.46e-01 | 0.2057 |
| 10158 | PDZK1IP1 | GSM4909291 | Human | Breast | IDC | 1.27e-07 | -4.97e-01 | 0.1753 |
| 10158 | PDZK1IP1 | GSM4909293 | Human | Breast | IDC | 1.39e-20 | -5.70e-01 | 0.1581 |
| 10158 | PDZK1IP1 | GSM4909294 | Human | Breast | IDC | 2.21e-16 | -5.23e-01 | 0.2022 |
| 10158 | PDZK1IP1 | GSM4909297 | Human | Breast | IDC | 1.52e-25 | -6.10e-01 | 0.1517 |
| 10158 | PDZK1IP1 | GSM4909298 | Human | Breast | IDC | 2.41e-09 | -3.95e-01 | 0.1551 |
| 10158 | PDZK1IP1 | GSM4909301 | Human | Breast | IDC | 7.81e-33 | -6.52e-01 | 0.1577 |
| 10158 | PDZK1IP1 | GSM4909302 | Human | Breast | IDC | 1.98e-13 | -5.01e-01 | 0.1545 |
| 10158 | PDZK1IP1 | GSM4909304 | Human | Breast | IDC | 8.04e-20 | -5.91e-01 | 0.1636 |
| 10158 | PDZK1IP1 | GSM4909306 | Human | Breast | IDC | 1.32e-02 | -3.24e-01 | 0.1564 |
| 10158 | PDZK1IP1 | GSM4909308 | Human | Breast | IDC | 5.71e-09 | -3.88e-01 | 0.158 |
| 10158 | PDZK1IP1 | GSM4909311 | Human | Breast | IDC | 1.66e-23 | -5.49e-01 | 0.1534 |
| 10158 | PDZK1IP1 | GSM4909312 | Human | Breast | IDC | 1.95e-08 | -4.16e-01 | 0.1552 |
| 10158 | PDZK1IP1 | GSM4909315 | Human | Breast | IDC | 4.28e-05 | -3.79e-01 | 0.21 |
| 10158 | PDZK1IP1 | GSM4909316 | Human | Breast | IDC | 7.26e-04 | -4.79e-01 | 0.21 |
| 10158 | PDZK1IP1 | GSM4909317 | Human | Breast | IDC | 4.92e-09 | -4.40e-01 | 0.1355 |
| 10158 | PDZK1IP1 | GSM4909318 | Human | Breast | IDC | 3.98e-06 | -6.57e-01 | 0.2031 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PDZK1IP1 | SNV | Missense_Mutation | c.137T>C | p.Ile46Thr | p.I46T | Q13113 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PDZK1IP1 | SNV | Missense_Mutation | c.230N>C | p.Val77Ala | p.V77A | Q13113 | protein_coding | tolerated(0.63) | benign(0) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| PDZK1IP1 | SNV | Missense_Mutation | novel | c.7G>A | p.Ala3Thr | p.A3T | Q13113 | protein_coding | tolerated_low_confidence(0.21) | benign(0.003) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| PDZK1IP1 | SNV | Missense_Mutation | rs150391778 | c.254N>T | p.Ser85Leu | p.S85L | Q13113 | protein_coding | tolerated(0.11) | benign(0.001) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PDZK1IP1 | SNV | Missense_Mutation | novel | c.196N>A | p.Leu66Met | p.L66M | Q13113 | protein_coding | tolerated(1) | benign(0) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| PDZK1IP1 | SNV | Missense_Mutation | novel | c.159C>A | p.Phe53Leu | p.F53L | Q13113 | protein_coding | tolerated(0.21) | probably_damaging(0.971) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| PDZK1IP1 | SNV | Missense_Mutation | c.259N>A | p.Ala87Thr | p.A87T | Q13113 | protein_coding | deleterious(0.05) | benign(0.118) | TCGA-BS-A0UL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PDZK1IP1 | SNV | Missense_Mutation | rs200717593 | c.107N>T | p.Ala36Val | p.A36V | Q13113 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PDZK1IP1 | SNV | Missense_Mutation | rs150391778 | c.254N>T | p.Ser85Leu | p.S85L | Q13113 | protein_coding | tolerated(0.11) | benign(0.001) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PDZK1IP1 | SNV | Missense_Mutation | rs200717593 | c.107C>T | p.Ala36Val | p.A36V | Q13113 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |